MedTrace Logo

Subretinal Macugen® for Neovascular Age-Related Macular Degeneration

NCT00788177 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-09-27

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of pegaptanib (Macugen®) for neovascular (exudative) age-related macular degeneration (AMD) when the first dose is administered to the submacular space instead of vitreous body in cases when previous state-of-the-art treatment for the AMD was deemed ineffective.

Conditions

  • Age-related Macular Degeneration

Interventions

DRUG

Pegaptanib (Macugen®)

Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Klinikum Ludwigshafen

    lead OTHER

Principal Investigators

  • Lars-Olof Hattenbach, MD · Department of ophthalmology, Ludwigshafen hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2012-03-31
Completion
2012-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00788177 on ClinicalTrials.gov